布地奈德福莫特罗干粉吸入剂治疗支气管哮喘患儿64例  

Clinical Efficacy of Budesonide Formoterol Dry Powder Inhalant in Treating 64 Children with Bronchial Asthma

作　　者：白玉荣[1] 

机构地区：[1]山东省警官总医院儿科,山东济南250002

出　　处：《中国药业》2015年第11期80-82,共3页China Pharmaceuticals

摘　　要：目的探讨布地奈德福莫特罗干粉吸入剂治疗支气管哮喘患儿的临床疗效。方法选择2011年9月至2013年2月就诊的中重度哮喘急性发作期患儿128例,随机分为试验组和对照组,每组64例。试验组给予布地奈德福莫特罗干粉吸入剂吸入,对照组给予布地奈德干粉吸入剂吸入,同时给予福莫特罗干粉吸入剂吸入。均治疗12周。观察并记录每日哮喘症状并评分,测定最大呼气峰流速(PEF)占预计值的百分比,流式细胞仪检测调节性T细胞(Treg)、Th1及Th2细胞的表达,每4周1次。结果治疗第4周、第8周、第12周后,两组哮喘评分均较治疗前明显下降(P<0.05),试验组均低于对照组(P<0.05);两组PEF占预计值百分比各时间段均较治疗前明显上升(P<0.05),且治疗第4周试验组高于对照组(P<0.05);两组Treg及Th1细胞百分率及Th1/Th2比值各时间段均较治疗前明显上升(P<0.05),且治疗第4周试验组较对照组上升明显(P<0.05);两组患者各时间段Th2细胞较治疗前明显下降(P<0.05),且治疗第4周试验组较对照组下降明显(P<0.05)。结论布地奈德福莫特罗干粉吸入剂对支气管哮喘患儿临床疗效可靠,能明显改善免疫紊乱状况,且不良反应少,值得推广。Objective To investigate the clinical efficacy of Budesonide Formoterol Dry Powder Inhalant in treating children＇s bronchial asthma. Methods 128 children patients with acute attack of moderate to severe asthma in our hospital from September 2011 to February 2013 were selected and randomly divided into the experimental group and the control group, 64 cases in each group. The experimental group was given the inhalation of Budesonide Formoterol Dry Powder Inhalant, while the control group received the inhalation of Budesonide Dry Powder Inhalant and simultaneous inhalation of Formoterol Dry Powder Inhalant. The treatment course was 12 weeks. The daily asthma symptoms and their scores were observed and recorded. The peak expiratory flow （PEF accounting for the predicted value% ） was detected, Treg and the expression of Th1 and Th2 cells were detected by the flow cytometry, once per 4 weeks, at the same time the liver, renal function and ECG before and after treatment were monitored in the two groups. The adverse reactions were observed and recorded. Results The asthma scores after 4-, 8-, 12- week treatment were significantly decreased compared with before treatment（ P 〈 0.05）, the asthma score in the experimental group was lower than that in the control group（P 〈 0. 05）; the PEF accounting for the predicted value （%） in various time periods was significantly increased compared with the before treatment（ P 〈 0. 05） and which in 4 week in the experimental group was higher than that in the control group（P 〈 0. 05）; the percentage of Treg and Thl cell and Th1/ Th2 ratio in various time periods were significantly increased compared with before treatment（ P 〈 0.05）, moreover which at 4 weeks in the experimental group was higher than that in the control group（ P 〈 0.05）; Th2 ceils in various time periods in the two groups were significantly decreased compared with before treatment（P 〈 0.05）, moreover the decrease at 4 weeks in the treatment group was more obvious compared

关 键 词：布地奈德 福莫特罗 干粉吸入剂 支气管哮喘 调节性T细胞 

分 类 号：R969.4[医药卫生—药理学] R974.3[医药卫生—药学]